Internal Medicine, Medical Oncology · Hackensack, NJ
NPI
1992951149
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
92 2nd St
Hackensack, NJ, 07601
Phone (551) 996-3925
Groups this clinician bills Medicare through
Medicare paid, 2024
$321K
12,098 services
Medicare patients, 2024
375
Average age 75
Drug cost, 2024
$8.9M
880 prescriptions
Company payments, 2025
$607K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James K McCloskey II was code J0885 (injection, epoetin alfa, (for non-esrd use), 1000 units), 6,100 times for 25 patients. In total James K McCloskey II billed 12,098 services in 32 codes, and Medicare paid $321K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 6,100 | 25 | $6.35 | $39K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,210 | 300 | $13.93 | $17K |
| 99214 Office E&M - Established | Office | 564 | 191 | $109.45 | $62K |
| 99215 Office E&M - Established | Office | 541 | 217 | $152.15 | $82K |
| 99213 Office E&M - Established | Office | 425 | 129 | $78.01 | $33K |
| 99233 Hospital E&M - Subsequent | Facility | 414 | 48 | $98.73 | $41K |
| 96372 Injection Administration | Office | 136 | 28 | $12.24 | $1,664 |
| 85097 Test - Miscellaneous | Office | 110 | 70 | $58.96 | $6,486 |
| 99223 Hospital E&M - Initial | Facility | 51 | 37 | $146.20 | $7,456 |
| 99238 Hospital Discharge Management | Facility | 47 | 31 | $68.99 | $3,243 |
| 99205 Office E&M - New | Office | 41 | 41 | $190.80 | $7,823 |
| 99232 Hospital E&M - Subsequent | Facility | 36 | 20 | $66.44 | $2,392 |
| 38220 Other Organ Systems | Office | 32 | 29 | $70.24 | $2,248 |
| 38221 Other Organ Systems | Office | 32 | 29 | $145.14 | $4,645 |
| 38222 Other Organ Systems | Office | 14 | 14 | $144.31 | $2,020 |
By year: 2022 $306K for 13,077 services; 2023 $272K for 9,667 services; 2024 $321K for 12,098 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,016 | 309 | $7.53 | $7,650 |
| 85027 Blood Count | 231 | 102 | $6.37 | $1,471 |
Medicare prescription drug claims, 2024
In 2024, the drug James K McCloskey II prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 148 prescriptions and refills. In total James K McCloskey II wrote 880 Medicare prescriptions that cost $8.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 148 | 148 | 25 | $2.6M |
| Inqovi Decitabine/Cedazuridine | 64 | 64 | 15 | $525K |
| Sprycel Dasatinib | 54 | 56 | Under 11 | $448K |
| Imatinib Mesylate Generic | 50 | 50 | Under 11 | $93K |
| Venclexta Venetoclax | 42 | 42 | 14 | $88K |
| Posaconazole Generic | 40 | 46 | 23 | $61K |
| Ayvakit Avapritinib | 33 | 33 | Under 11 | $1.1M |
| Bosulif Bosutinib | 33 | 33 | Under 11 | $434K |
| Hydroxyurea Generic | 32 | 42 | 15 | $470 |
| Acyclovir Generic | 32 | 40 | 16 | $417 |
| Tasigna Nilotinib Hcl | 30 | 30 | Under 11 | $461K |
| Ondansetron Hcl Generic | 29 | 29 | Under 11 | $174 |
| Ojjaara Momelotinib Dihydrochloride | 24 | 24 | Under 11 | $650K |
| Promacta Eltrombopag Olamine | 19 | 19 | Under 11 | $517K |
| Ciprofloxacin Hcl Generic | 17 | 21 | Under 11 | $418 |
Brand drugs: 540 claims; generic drugs: 340 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James K McCloskey II $607K ($607K in general payments such as food, travel and fees) from 33 companies. The largest payer was GlaxoSmithKline, LLC. with $108K.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 66 | $108K |
| Syndax Pharmaceuticals, Inc. SNDX | 47 | $100K |
| Sobi, Inc SOBI.ST | 36 | $69K |
| Geron Corporation GERN | 43 | $68K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 29 | $60K |
| PharmaEssentia USA Corporation 6446.TW | 36 | $60K |
| Sanofi US Services Inc. SNY | 29 | $36K |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $27K |
| Incyte Corporation INCY | 18 | $25K |
| Rigel Pharmaceuticals, Inc. RIGL | 13 | $21K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.